Bausch Health Companies Inc.: Opioid-Induced Constipation trials

The registry lists 13 Opioid-Induced Constipation studies with Bausch Health Companies Inc. as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 2 4Phase 3 5Phase 4 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Compassionate Use Study of MethylnaltrexoneCompletedNCT01368562Not applicableResults posted
• A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant PainCompletedNCT01186770Phase 3Results posted
• Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-ConstipationCompletedNCT00936884Phase 3Results posted
• Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced ConstipationCompletedNCT00804141Phase 3Results posted
• Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced IllnessCompletedNCT00672477Phase 4Results posted
• Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced IllnessCompletedNCT00672139Phase 4Results posted
• Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic ProceduresCompletedNCT00640146Phase 2Results posted
• Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant PainCompletedNCT00529087Phase 3Results posted
• Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)CompletedNCT01983306Phase 2
• Methylnaltrexone in Patients With Opioid-Induced Bowel DysfunctionCompletedNCT01367574Phase 2
• Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer SubjectsWithdrawnNCT00858754Phase 4
• A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness PatientsCompletedNCT00401362Phase 3
• Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant PainCompletedNCT00366431Phase 2